Comparing the current results to its competitors, Krystal Biotech Inc reported Revenue increase in the 2 quarter 2026 by 24.14 % year on year. The sales growth was above Krystal Biotech Inc 's competitors' average revenue growth of 21.9 %, achieved in the same quarter.
Krystal Biotech Inc 's Comment on Competition and Industry Peers
The gene therapy sector is characterized by rapid technological advancements and a focus on proprietary products, with competitors often possessing greater financial resources and larger research and development teams. For the treatment of Dystrophic Epidermolysis Bullosa (DEB), VYJUVEK is the first corrective therapy approved globally. Competitors in this field are categorized into Corrective Approaches and Palliative Treatments. Corrective Approaches include companies such as Abeona Therapeutics Inc. and Castle Creek Biosciences, Inc., which develop or have commercialized autologous or grafting gene therapy methods. Abeona Therapeutics Inc.'s product Zevaskyn® received FDA approval in 2025. BridgeBio Pharma, Inc., through its affiliate Phoenix Tissue Repair, is developing a recombinant-protein-based approach. Palliative Treatments are offered by companies including Chiesi Farmaceutici S.p.A. and RHEACELL GmbH & Co.
October 14, 2025
Krystal Biotech, Inc., a biopharmaceutical company based in Pittsburgh, announced on October 14, 2025, that the U.S. Food and Drug Administration (FDA) has granted platform technology designation to its innovative gene therapy, KB801. This therapy utilizes a genetically modified, non-replicating herpes simplex virus type 1 (HSV-1) viral vector for the treatment of neurotrophic keratitis (NK), a condition that can lead to visual impairment due to corneal damage.The platform technology designation represents a significant milestone for Krystal Biotech, as it recognizes the potential of the HSV-1 viral vector in developing new treatments. KB801 is currently being evaluated in a randomized, placebo-controlled cl...
February 28, 2025
In a significant development for genetic medicine, Krystal Biotech, Inc. a pioneering biotechnology firm based in Pittsburgh, has received a positive opinion from the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning its revolutionary product, VYJUVEK. This gene therapy, also known as beremagene geperpavec-svdt (B-VEC), is being evaluated for its potential to address the crippling genetic disorder known as dystrophic epidermolysis bullosa (DEB).Dystrophic epidermolysis bullosa, a rare yet devastating condition, causes the skin to become extremely fragile, leading to severe blistering and wounds that can result in progressive scarring and disability. Current tr...
December 12, 2024
In a landmark development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Krystal Biotech has announced promising early clinical findings from its innovative gene therapy programs, KB408 and KB407. These findings suggest effective gene delivery and therapeutic protein expression in the lungs of patients suffering from this rare respiratory condition, potentially paving the way for a new treatment paradigm. Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder characterized by insufficient levels of the protein alpha-1 antitrypsin (AAT), leading to severe lung and liver disease. Individuals with AATD are at risk of developing chronic obstructive pulmonary disease (COPD), emphysema, and live...
August 5, 2024
Krystal Biotech s Promising Advances in Gene Therapy: A Closer Look at Recent DevelopmentsIn an exciting update for both the biotechnology and healthcare sectors, Krystal Biotech, Inc. recently announced its financial results for the second quarter of 2024, complemented by significant business updates. Most notably, the company reported impressive net product revenue of $70.3 million for Q2 alone, amounting to $166.2 million since the launch of its innovative gene therapy product, B-VEC, in August 2023. This robust financial performance underscores the burgeoning demand for Krystal s solutions, which target critical unmet medical needs.An extraordinary highlight of Krystal Biotech s recent accomplishments i...
February 8, 2024
Krystal Biotech s Groundbreaking B-VEC Treatment: A Promising Breakthrough for Ocular Complications in Dystrophic Epidermolysis Bullosa PatientsKrystal Biotech has recently published a groundbreaking study in the prestigious New England Journal of Medicine, shedding light on the remarkable potential of their B-VEC treatment in managing ocular complications in patients with Dystrophic Epidermolysis Bullosa (DEB). This incredible development not only signifies a significant advancement in the field of ocular medicine but also highlights the versatility of Krystal s HSV-1 platform for addressing various ocular diseases.Dystrophic Epidermolysis Bullosa is a rare genetic disorder characterized by extremely fragil...
Voyager Therapeutics Inc. is a biopharmaceutical company that focuses on the development of gene therapies to treat severe neurological diseases. Their business model revolves around research, development, and commercialization of innovative treatments using viral gene therapy technology.
Protalix Biotherapeutics Inc. operates under a business model focused on the development, production, and commercialization of recombinant therapeutic proteins using plant cell culture technology, aiming to address unmet medical needs and provide innovative treatment options to patients worldwide.
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Krystal Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Krystal Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
